Chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Andersson, J., Skansen-Saphir, U., Sparrelid, E., & Andersson, U. (1996). Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol, 104(Suppl 1), 10–20.
Andersson, U., Bjork, L., Skansen-Saphir, U., & Andersson, J. (1994). Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev, 139, 21–42.
Arad, G., Levy, R., Hillman, D., & Kaempfer, R. (2000). Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med, 6, 414–421.
Arend, W. P., Smith, M. F., Jr., Janson, R. W., & Joslin, F. G. (1991). IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol, 147, 1530–1536.
Asano, T., & Ogawa, S. (2000). Expression of IL-8 in Kawasaki disease. Clin Exp Immunol, 122, 514–519.
Ashbaugh, C. D., Warren, H. B., Carey, V. J., & Wessels, M. R. (1998). Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J Clin Invest, 102, 550–560.
Baird, R. W., Bronze, M. S., Kraus, W., Hill, H. R., Veasey, L. G., & Dale, J. B. (1991). Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium. J Immunol, 146, 3132–3137.
Ballow, M. (1997). Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol, 100, 151–157.
Barnham, M., & Anderson, A. W. (1997). Non-steroidal anti-inflammatory drugs: A predisposing factor for streptococcal bacteremia. In Horaud (Ed.), Streptococci and the host. New York: Plenum Press.
Barry, W., Hudgins, L., Donta, S. T., & Pesanti, E. L. (1992). Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA, 267, 3315–3316.
Basiliere, J. L., Bistrong, H. W., & Spence, W. F. (1968). Streptococcal pneumonia. Recent outbreaks in military recruit populations. Am J Med, 44, 580–589.
Basma, H. (1998). Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): Potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun, 66, 2279–2283.
Basma, H., Norrby-Teglund, A., Guedez, Y., McGeer, A., Low, D. E., El-Ahmedy, O., Schwartz, B., & Kotb, M. (1999). Risk factors in the pathogenesis of invasive group A streptococcal infections: Role of protective humoral immunity. Infect Immun, 67, 1871–1877.
Bates, J. H., Campbell, G. D., Barron, A. L., McCracken, G. A., Morgan, P. N., Moses, E. B., & Davis, C. M. (1992). Microbial etiology of acute pneumonia in hospitalized patients. Chest, 101, 1005–1012.
Beachey, E. H., Bronze, M., Dale, J. B., Kraus, W., Poirier, T., & Sargent, S. (1988). Protective and autoimmune epitopes of streptococcal M proteins. Vaccine, 6, 192–196.
Berge, A., & Bjorck, L. (1995). Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins. J Biol Chem, 270, 9862–9867.
Bessen, D. E., & Fischetti, V A. (1990). Differentiation between two biologically distinct classes of group A streptococci by limited substitutions of amino acids within the shared region of M protein-like molecules. J Exp Med, 172, 1757–1764.
Bhakdi, S., Klonisch, T., Nuber, P., & Fischer, W. (1991). Stimulation of monokine production by lipoteichoic acids. Infect Immun, 59, 4614–4620.
Bisno, A. L., & Stevens, D. L. (1996). Streptococcal infections of skin and soft tissues. N Eng J Med, 334, 240–245.
Bjorck, L., Akesson, P., Bohus, M., Trojnar, J., Abrahamson, M., Olafsson, I., & Grubb, A. (1989). Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor. Nature, 337, 385–386.
Boyle, M. D. (1995). Variation of multifunctional surface binding proteins—a virulence strategy for group A streptococci? J Theor Biol, 173, 415–426.
Brandt, E. R., Sriprakash, K. S., Hobb, R. I., Hayman, W. A., Zeng, W., Batzloff, M. R., Jackson, D. C., & Good, M. F. (2000). New multi-determinant strategy for a group A Streptococcal vaccine designed for the Australian Aboriginal population. Nat Med, 6, 455–459.
Brogan, T. V., Nizet, V., Waldhausen, J. H., Rubens, C. E., & Clarke, W. R. (1995). Group A Streptococcal necrotizing fasciitis complicating primary varicella: A series of fourteen patients. Pediatr Infect Dis J, 14, 588–594.
Bronze, M. S., & Dale, J. B. (1993). Epitopes of Streptococcal M proteins that evoke antibodies that cross-react with human brain. J Immunol, 151, 2820–2828.
Brown, D. R., Davis, N. L., Lepawsky, M., Cunningham, J., & Kortbeek, J. (1994). A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg, 167, 485–489.
Burns, E. H., Jr., Marciel, A. M., & Musser, J. M. (1996). Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease. Infect Immun, 64, 4744–4750.
Card, G. L., Jasuja, R. R., & Gustafson, G. L. (1994). Activation of arachidonic acid metabolism in mouse macrophages by bacterial amphiphiles. J Leukoc Biol, 56, 723–728.
Cawley, M. J., Briggs, M., Haith, L. R., Jr., Reilly, K. J., Guilday, R. E., Braxton, G. R., & Patton, M. L. (1999). Intravenous immunoglobulin as adjunctive treatment for Streptococcal toxic shock syndrome associated with necrotizing fasciitis: Case report and review. Pharmacotherapy, 19, 1094–1098.
Chatellier, S., & Kotb, M. (2000). Preferential stimulation of human lymphocytes by oligodeoxynu-cleotides that copy DNA CpG motifs present in virulent genes of group A streptococci. Eur J Immunol, 30, 993–1001.
Chelsom, J., Halstensen, A., Haga, T., & Hoiby, E. A. (1994). Necrotising fasciitis due to group A streptococci in western Norway: Incidence and clinical features. Lancet, 344, 1111–1115.
Chiu, C. H., Ou, J. T., Chang, K. S., & Lin, T. Y. (1997). Successful treatment of severe Streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics. Infection, 25, 47–48.
Cockerill, F. R. I., MacDonald, K. L., Thompson, R. L., Roberson, F., Kohner, P. C., Besser-Wiek, J., Manahan, J. M., Musser, J. M., Schlievert, P. M., Talbot, J., Frankfort, B., Steckelberg, J. M., Wilson, W. R., Osterholrn, M. T., & The Investigation Team. (1997). An outbreak of invasive group A Streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA, 277, 38–43.
Colman, G., Tanna, A., Efstratiou, A., & Gaworzewska, E. (1993). The serotypes of Streptococcus pyogenes present in Britain during 1980–1990 and their association with disease. J Med Microbiol, 39, 165–178.
Cone, L. A., Woodward, D. R., Schlievert, P. M., & Tomory, G. S. (1987). Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med, 317, 146–149.
Couper, R. (1997). Invasive group A Streptococcal infections. N Engl J Med, 336, 513.
Courtney, H. S., Dale, J. B., & Hasty, D. L. (1996). Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells. Infect Immun, 64, 2415–2419.
Courtney, H. S., Hasty, D. L., Li, Y., Chiang, H. C., Thacker, J. L., & Dale, J. B. (1999). Serum opacity factor is a major fibronectin-binding protein and a virulence determinant of M type 2 Streptococcus pyogenes. Mol Microbiol, 32, 89–98.
Courtney, H. S., Li, Y., Dale, J. B., & Hasty, D. L. (1994). Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci. Infect Immun, 62, 3937–3946.
Cunningham, M. W. (2000). Pathogenesis of group A streptococcal infections. Clin Microbiol Rev, 13, 470–511.
Cywes, C., Stamenkovic, I., & Wessels, M. R. (2000). CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J Clin Invest, 106, 995–1002.
Dale, J. B. (1999a). Group A streptococcal vaccines. Infect Dis Clin North Am, 13, 227–243, viii.
Dale, J. B. (1999b). Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine, 17, 193–200.
Dale, J. B., & Beachey, E. H. (1985). Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med, 162, 583–591.
Dale, J. B., Chiang, E. Y, Liu, S., Courtney, H. S., & Hasty, D. L. (1999). New protective antigen of group A streptococci. J Clin Invest, 103, 1261–1268.
Dale, J. B., Washburn, R. G., Marques, M. B., & Wessels, M. R. (1996). Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun, 64, 1495–1501.
Darville, T., Milligan, L. B., & Laffoon, K. K. (1997). Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production. Infect Immun, 65, 366–372.
Davies, H. D, Matlow, A., Carroll, K., & Curley, F. J. (1994). Apparent lower rates of streptococcal toxic shock syndrome and lower mortality in children with invasive group A streptococcal infections compared with adults. Pediatr Infect Dis J, 13, 49–56.
Davies, H. D., McGeer, A., Schwartz, B., Green, K., Cann, D., Simor, A. E., Low, D. E., & The Ontario Group A Streptococcal Study Group. (1996). Invasive group A streptococcal infections in Ontario, Canada. N Eng J Med, 335, 547–554.
De Kimpe, S. J., Hunter, M. L., Bryant, C. E., Thiemermann, C., & Vane, J. R. (1995a). Delayed circulatory failure due to the induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in anaesthetized rats. Br J Pharmacol, 114, 1317–1323.
De Kimpe, S. J., Kengatharan, M., Thiemermann, C., & Vane, J. R. (1995b). The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci USA, 92, 10359–10363.
Demers, B., Simor, A. E., Vellend, H., Schlievert, P. M., Byrne, S., Jamieson, F. B., Walmsley, S., & Low, D. E. (1993). Severe invasive group A streptococcal infections in Ontario, Canada: 1987–1991. Clin Inf Dis, 16, 792–800.
Descamps, V, Aitken, J., & Lee, M. G. (1994). Hippocrates on necrotising fasciitis. Lancet, 344, 556.
DiPersio, J. R., File, T. M., Jr., Stevens, D. L., Gardner, W. G., Petropoulos, G., & Dinsa, K. (1996). Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Inf Dis, 22, 490–95.
Doctor, A., Harper, M. B., & Fleisher, G. R. (1995). Group A beta-hemolytic streptococcal bacteremia: Historical overview, changing incidence, and recent association with varicella. Pediatrics, 96, 428–433.
Duma, R. J., Weinberg, A. N., Medrek, T. F., & Kunz, L. J. (1969). Streptococcal infections: A bacteriologic and clinical study of streptococcal bacteremia. Medicine, 48, 87–127.
Eriksson, B. K., Andersson, J., Holm, S. E., & Norgren, M. (1999). Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis, 180, 410–418.
Fang, G. D., Fine, M., Orloff, J., Arisumi, D., Yu, V L., Kapoor, W., Grayston, J. T., Wang, S. P., Kohler, R., & Muder, R. R. (1990). New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore), 69, 307–316.
Fischetti, V. A. (1989). Streptococcal M protein: Design and biological behavior. Clin Microbiol Rev, 2, 285–314.
Gaworzewska, E., & Colman, G. (1988). Changes in the pattern of infection caused by Streptococcus pyogenes. Epidem Inf, 100, 257–269.
Gemmell, C. G., Peterson, P. K., Schmeling, D., Kim, Y., Mathews, J., Wannamaker, L., & Quie, P. G. (1981). Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest, 67, 1249–1256.
Goepel, J. R., Richards, D. G., Harris, D. M., & Henry, L. (1980). Fulminant Streptococcus pyogenes infection. Brit Med J, 281, 1412.
Guzman, C. A., Talay, S. R., Molinari, G., Medina, E., & Chhatwal, G. S. (1999). Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis, 179, 901–906.
Hable, K. A., Horstmeirer, C., Wold, A. D., & Washington, J. A. (1973). Group A β-hemolytic streptococcemia: Bacteriologic and clinical study of 44 cases. Mayo Clin Proc, 48, 336–339.
Hackett, S. P., & Stevens, D. L. (1992). Streptococcal toxic shock syndrome: Synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis, 165, 879–885.
Hasty, D. L., Ofek, I., Courtney, H. S., & Doyle, R. J. (1992). Multiple adhesins of streptococci. Infect Immun, 60, 2147–2152.
Haywood, C. T., McGeer, A., & Low, D. E. (1998). Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995–1997. Abstract of Canadian Society for Plastic Surgeons Annual Meeting. Ref Type: Abstract.
Heeg, K., Sparwasser, T., Lipford, G. B., Hacker, H., Zimmermann, S., & Wagner, H. (1998). Bacterial DNA as an evolutionary conserved ligand signalling danger of infection to immune cells. Eur J Clin Microbiol Infect Dis, 17, 464–469.
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., & Akira, S. (2000). A Toll-like receptor recognizes bacterial DNA. Nature, 408, 740–745.
Herwald, H., Collin, M., Muller-Esterl, W., & Bjorck, L. (1996). Streptococcal cysteine proteinase releases kinins: A novel virulence mechanism. J Exp Med, 184, 665–673.
Heumann, D., Barras, C., Severin, A., Glauser, M. P., & Tomasz, A. (1994). Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun, 62, 2715–2721.
Hiemstra, P. S., Brands-Tajouiti, J., & van Furth, R. (1994). Comparison of antibody activity against various microorganisms in intravenous immunoglobulin preparations determined by ELISA and opsonic assay. J Lab Clin Med, 123, 241–246.
Hoe, N. P., Nakashima, K., Lukomski, S., Grigsby, D., Liu, M., Kordari, P., Dou, S. J., Pan, X., Vuopio-Varkila, J., Salmelinna, S., McGeer, A., Low, D. E., Schwartz, B., Schuchat, A., Naidich, S., De Lorenzo, D., Fu, Y. X., & Musser, J. M. (1999). Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves. Nat Med, 5, 924–929.
Hoge, C. W., Schwartz, B., Talkington, D. F., Breiman, R. F., MacNeill, E. M., & Englender, S. J. (1993a). The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. JAMA, 269, 585–589.
Hoge, C. W., Schwartz, B., Talkington, D. F., Breiman, R. F., MacNeill, E. M., & Englender, S. J. (1993b). The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study [published erratum appears in JAMA, 1993, Apr 7, 269(13), 1638] [see comments]. JAMA, 269, 384–389.
Holm, S. E., Norrby, A., Bergholm, A. M., & Norgren, M. (1992). Aspects of pathogenesis of serious group A streptococcal infections in Sweden. J Infect Dis, 166, 31–37.
Hook, E. W., Horton, C. A., & Schaberg, D. R. (1983). Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA, 249, 1055–1057.
Husmann, L. K., Yung, D.-L., Hollingshead, S. K., & Scott, J. R. (1997). Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia. Infect Immun, 65, 1422–1430.
Hytonen, J., Haataja, S., Gerlach, D., Podbielski, A., & Finne, J. (2001). The SpeB virulence factor of Streptococcus pyogenes, a multifunctional secreted and cell surface molecule with strepadhesin, laminin-binding and cysteine protease activity. Mol Microbiol, 39, 512–519.
Jaffe, J., Natanson-Yaron, S., Caparon, M. G., & Hanski, E. (1996). Protein F2, a novel fibronectin-binding protein from Streptococcus pyogenes, possesses two binding domains. Mol Microbiol, 21, 373–384.
Ji, Y, Carlson, B., Kondagunta, A., & Cleary, P. P. (1997). Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun, 65, 2080–2087.
Kamezawa, Y., Nakahara, T., Nakano, S., Abe, Y., Nozaki-Renard, J., & Isono, T. (1997). Streptococcal mitogenic exotoxin Z, a novel acidic superantigenic toxin produced by a T1 strain of Streptococcus pyogenes. Infect Immun, 65, 3828–3833.
Kansal, R. G., McGeer, A., Low, D. E., Norrby-Teglund, A., & Kotb, M. (2000). Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect Immun, 68, 6362–6369.
Kaplan, E. (1993). Global assessment of rheumatic fever and rheumatic heart disease at the close of the century. The influences and dynamics of population and pathogens: A failure to realize prevention? (The T. Duckettt Jones Memorial Lecture.) Circulation, 88, 1964–1972.
Kaplan, E. L. (1996). Recent epidemiology of group A streptococcal infections in North America and abroad: An overview. Paediatrics, 97, 945–948.
Kapur, V., Maffei, J. T., Greer, R. S., Li, L. L., Adams, G. J., & Musser, J. M. (1994). Vaccination with streptococcal extracellular cysteine protease (interleuki-1β convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog, 16, 443–450.
Kapur, V., Majesky, M. W., Li, L. L., Black, R. A., & Musser, J. M. (1993a). Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci USA, 90, 7676–7680.
Kapur, V., Topouzis, S., Majesky, M. W., Li, L. L., Hamrick, M. R., Hamill, R. J., Patti, J. M., & Musser, J. M. (1993b). A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. Microb Pathog, 15, 327–346.
Katz, A. R., & Morens, D. M. (1992). Severe streptococcal infections in historical perspective. Clin Infect Dis, 14, 298–307.
Kaul, R., McGeer, A., Low, D. E., Green, K., Schwartz, B., Ontario Group A Streptococcal Study, & Simor, A. E. (1997). Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators and microbiologic analysis of 77 cases. Am J Med, 103, 18–24.
Kaul, R., McGeer, A., Norrby-Teglund, A., Kotb, M., Schwartz, B., O’Rourke, K., Talbot, J., The Canadian Streptococcal Study Group, & Low, D. E. (1999). Intravenous immunoglobulin therapy in streptococcal toxic shock syndrome—A comparative observational study. Clin Inf Dis, 28, 800–807.
Kawabata, S., Kunitomo, E., Terao, Y., Nakagawa, I., Kikuchi, K., Totsuka, K., & Hamada, S. (2001). Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun, 69, 924–930.
Keefer, C. S., Inglefinger, F. J., & Spink, W. W. (1937). Significance of hemolytic streptococci bacteraemia: A study of two hundred and forty six patients. Arch Intern Med, 60, 1084–1097.
Keefer, C. S., Rantz, L. A., & Rammelkamp, C. H. (1941). Hemolytic streptococcal pneumonia and empyema: A study of 55 cases with special reference to treatment. Ann Intern Med, 14, 1533–1550.
Keller, R., Fischer, W., Keist, R., & Bassetti, S. (1992). Macrophage response to bacteria: Induction of marked secretory and cellular activities by lipoteichoic acids. Infect Immun, 60, 3664–3672.
Kengatharan, K. M., De Kimpe, S. J., & Thiemermann, C. (1996). Role of nitric oxide in the circulatory failure and organ injury in a rodent model of Gram-positive shock. Br J Pharmacol, 119, 1411–1421.
Kiska, D. L., Thiede, B., Caracciolo, J., Jordan, M., Johnson, D., Kaplan, E. L., Gruninger, R. P., Lohr, J. A., Gilligan, P. H., & Denny, F. W., Jr. (1997). Invasive group A streptococcal infections in North Carolina: Epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis, 176, 992–1000.
Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J., & Krieg, A. M. (1996). CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA, 93, 2879–2883.
Kotb, M. (1995). Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev, 8, 411–426.
Kotb, M. (1998). Superantigens of Gram-positive bacteria: Structure-function analyses and their implications for biological activity. Curr Opin Microbiol, 1, 56–65.
Kraus, W., & Beachey, E. H. (1988). Renal autoimmune epitope of group A streptococci specified by M protein tetrapeptide Ile-Arg-Leu-Arg. Proc Natl Acad Sci USA, 85, 4516–4520.
Kreikemeyer, B., Talay, S. R., & Chhatwal, G. S. (1995). Characterization of a novel fibronectin-binding surface protein in group A streptococci. Microb Pathog, 19, 299–315.
Krieg, A. M. (1995). CpG DNA: A pathogenic factor in systemic lupus erythematosus? J Clin Immunol, 15, 284–292.
Kuo, C. F., Wu, J. J., Lin, K. Y., Tsai, P. J., Lee, S. C., Jin, Y. T., Lei, H. Y., & Lin, Y. S. (1998). Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection. Infect Immun, 66, 3931–3935.
Lamothe, F., D’Amico, P., Ghosn, P., Tremblay, C., Braidy, J., & Patenaude, J. V (1995). Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: Case report and review. Clin Inf Dis, 21, 1469–1470.
Lancefield, R. C. (1962). Current knowledge of the type specific M antigens of group A streptococci. J Immunol, 89, 307–313.
Laupland, K. B., Davies, H. D., Low, D. E., Schwartz, B., Green, K., & McGeer, A. (2000). Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics, 105, E60.
Leung, D. Y., Cotran, R. S., Kurt-Jones, E., Burns, J. C., Newburger, J. W., & Pober, J. S. (1989). Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet, 2, 1298–1302.
Lieberman, D., Schlaeffer, F., Boldur, I., Lieberman, D., Horowitz, S., Friedman, M. G., Leiononen, M., Horovitz, O., Manor, E., & Porath, A. (1996). Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients. Thorax, 51, 179–184.
Lim, I., Shaw, D. R., Stanley, D. P., Lumb, R., & McLennan, G. (1989). A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust, 151, 87–91.
Limbago, B., Penumalli, V., Weinrick, B., & Scott, J. R. (2000). Role of streptolysin O in a mouse model of invasive group A streptococcal disease. Infect Immun, 68, 6384–6390.
Lissner, R., Struff, W. G., Autenrieth, I. B., Woodcock, B. G., & Karch, H. (1999). Efficacy and potential clinical applications of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion. Eur J Surg Suppl, 584, 17–25.
Low, D. E., Schwartz, B., & McGeer, A. (1997). The reemergence of severe group A streptococcal disease: An evolutionary perspective. In W. M. Scheld, D. Armstrong, & J. M. Hughes (Eds.), Emerging infections 1 (pp. 93–123). Washington, DC: ASM Press.
Lukomski, S., Nakashima, K., Abdi, I., Cipriano, V. J., Ireland, R. M., Reid, S. D., Adams, G. G., & Musser, J. M. (2000). Identification and characterization of the scl geneencoding a group A Streptococcus extracellular protein virulence factor with similarity to human collagen. Infect Immun, 68, 6542–6553.
Lukomski, S., Sreevatsan, S., Amberg, C., Reichardt, W., Woischnik, M., Podbielski, A., & Musser, J. M. (1997). Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains. J Clin Invest, 99, 2574–2580.
MacCallum, W. G. (1919). The pathology of the pneumonia in the United States army camps during the winter of 1917–1918 (Monograph No. 10). New York: Rockefeller Institute for Medical Research.
Mahieu, L. M., Holm, S. E., Goossens, H. J., & Van Acker, K. J. (1995). Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J Pediatr, 127, 987–989.
Marrack, P., & Kappler, J. (1990). The staphylococcal enterotoxins and their relatives. Science, 248, 705–711.
Marston, B. J., Plouffe, J. F., File, T. M., Jr., Hackman, B. A., Salstrom, S. J., Lipman, H. B., Kolczak, M. S., & Breiman, R. F. (1997). Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med, 157, 1709–1718.
Martin, P. R., & Hoiby, E. A. (1990). Streptococcal serogroup A epidemic in Norway 1987–1988. Scand J Infect Dis, 22, 421–429.
Mascini, E. M., Jansze, M., Schellekens, J. F., Musser, J. M., Faber, J. A., Verhoef-Verhage, L. A., Schouls, L., van Leeuwen, W. J., Verhoef, J., & van Dijk, H. (2000). Invasive group A streptococcal disease in the Netherlands: Evidence for a protective role of anti-exotoxin A antibodies. J Infect Dis, 181, 631–638.
Mascini, E. M., Jansze, M., Schouls, L. M., Verhoef, J., & van Dijk, H. (2001). Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents, 18, 395–398.
Mattsson, E., Verhage, L., Rollof, J., Fleer, A., Verhoef, J., & van Dijk, H. (1993). Peptidoglycan and teichoic acid from Staphylococcus epidermidis stimulate human monocytes to release tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6. FEMS Immunol Med Microbiol, 7, 281–287.
McCormick, J. K., Yarwood, J. M., & Schlievert, P. M. (2001). Toxic shock syndrome and bacterial superantigens: An update. Annu Rev Microbiol, 55, 77–104.
McGeer, A., Willey, B., Schwartz, B., Green, K., Bernston, A., Trpeski, L., Talbot, J., Group A Streptococcal Study, & Low, D. E. (1998). Epidemiology of invasive GAS disease due to M3 serotypes in Ontario, Canada. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract no. 577. Abstract.
McLellan, D. G., Chiang, E. Y., Courtney, H. S., Hasty, D. L., Wei, S. C., Hu, M. C., Walls, M. A., Bloom, J. J., & Dale, J. B. (2001). Spa contributes to the virulence of type 18 group A streptococci. Infect Immun, 69, 2943–2949.
Medaglini, D., Pozzi, G., King, T. P., & Fischetti, V. A. (1995). Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oralcolonization. Proc Natl Acad Sci USA, 92, 6868–6872.
Medzihtov, R., & Janeway, C. J., Jr. (2000). Innate immunity. N Engl J Med, 5, 338–344.
Metlay, J. P., Hermann, J., Cetron, M. S., Fine, M. J., Farley, M. M., Whitney, C., & Breiman, R. F. (2000). Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis, 30, 520–528.
Mollick, J. A., Miller, G. G., Musser, J. M., Cook, R. G., Grossman, D., & Rich, R. R. (1993). A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest, 92, 710–719.
Morath, S., Geyer, A., & Hartung, T. (2001). Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med, 193, 393–397.
Moses, A. E., Wessels, M. R., Zalcman, K., Alberti, S., Natanson-Yaron, S., Menes, T., & Hanski, E. (1997). Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect Immun, 65, 64–71.
Mouthon, L., Kaveri, S. V., Spalter, S. H., Lacroix-Desmazes, S., Lefranc, C., Desai, R., & Kazatchkine, M. D. (1996). Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol, 104(Suppl. 1), 3–9.
Muller, M. P., McGeer, A., Low, D. E., & Ontario Group A Streptococcal Study. (2001). Successful outcomes in six patients treated conservatively for suspected necrotizing fasciitis (NF) due to group A streptococcus (GAS). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Ref Type: Abstract.
Muller, M. P., McGeer, A. J., Low, D. E., & the Ontario Group A Streptococcal Study Group. (2000). Clinical and epidemiological features of group A Streptococcal pneumonia in Ontario, Canada: 1992 to 1996. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Ref Type: Abstract.
Nadal, D., Lauener, R. P., & Braegger, C. P. (1993). T cell activation and cytokine release in Streptococcal toxic shock-like syndrome. J Pediatr, 122, 727–729.
Nakashima, K., Ichiyama, S., Linuma, Y., Hasegawa, Y., Ohta, M., Ooe, K., Shimizu, Y., Igarashi, H., Murai, T., & Shimokata, K. (1997). A clinical and bacteriologic investigation of invasive Streptococcal infections in Japan on the basis of serotypes, toxin production, and genomic DNA fingerprints. Clin Infect Dis, 25, 260–266.
Navarre, W. W., & Schneewind, O. (1999). Surface proteins of Gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev, 63, 174–229.
Norrby-Teglund, A., Basma, H., Andersson, J., McGeer, A., Low, D. E., & Kotb, M. (1998). Varying titers of neutralizing antibodies to Streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: Implications for therapeutic efficacy [see comments]. Clin Infect Dis, 26, 631–638.
Norrby-Teglund, A., Ihendyane, N., Kansal, R., Basma, H., Kotb, M., Andersson, J., & Hammarstrom, L. (2000). Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A Streptococcal superantigens. Clin Infect Dis, 31, 1175–1182.
Norrby-Teglund, A., Kaul, R., Low, D. E., McGeer, A., Andersson, J., Andersson, U., & Kotb, M. (1996a). Evidence for the presence of Streptococcal superantigen neutralizing antibodies in normal polyspecific IgG (IVIG). Infect Immun, 64, 5395–5398.
Norrby-Teglund, A., Kaul, R., Low, D. E., McGeer, A., Newton, D. W., Andersson, J., Andersson, U., & Kotb, M. (1996b). Plasma from patients with severe group A Streptococcal infections treated with normal polyspecific IgG (IVIG) inhibitsStreptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol, 156, 3057–3064.
Norrby-Teglund, A., Pauksens, K., Holm, S. E., & Norgren, M. (1994). Relation between low capacity of human sera to inhibit Streptococcal mitogens and serious manifestations of disease. J Inf Dis, 170, 585–591.
Norrby-Teglund, A., & Stevens, D. L. (1998). Novel therapies in Streptococcal toxic shock syndrome: Attenuation of virulence factor expression and modulation of the host response. Curr Opin Infect Dis, 11, 285–291.
Pancholi, V., & Fischetti, V A. (1992). A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding activity. J Exp Med, 176, 415–426.
Pancholi, V., & Fischetti, V. A. (1998). Alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem, 273, 14503–14515.
Parker, M. T. (1979). Necropsy studies of the bacterial complications of influenzae. J Infect, 1(Suppl 2), 9–16.
Patel, R., Rouse, M. S., Florez, M. V., Piper, K. E., Cockerill, F. R., Wilson, W. R., & Steckelberg, J. M. (2000). Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. J Infect Dis, 181, 230–234.
Perez, C. M., Kubak, B. M., Cryer, H. G., Salehmugodam, S., Vespa, P., & Farmer, D. (1997). Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: Case report and review. Am J Med, 102, 111–112.
Peterson, C. L., Mascola, L., Chao, S. M., Lieberman, J. M., Arcinue, E. L., Blumberg, D. A., Kim, K. S., Kovacs, A., Wong, V. K., & Brunell, P. A. (1996a). Children hospitalized for varicella: A prevaccine review. J Pediatr, 129, 529–536.
Peterson, C. L., Vugia, D. J., Meyers, H. B., Chao, S. M., Vogt, J., Lanson, J., Brunell, P. A., Kim, K. S., & Mascola, L. (1996b). Risk factors for invasive group A streptococcal infections in children with varicella: A case-control study. Pediatr Infect Dis J, 15, 151–156.
Poutsiaka, D. D., Clark, B. D., Vannier, E., & Dinarello, C. A. (1991). Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood, 78, 1275–1281.
Proft, T., Moffatt, S. L., Berkahn, C. J., & Fraser, J. D. (1999). Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med, 189, 89–102.
Pruksakorn, S., Currie, B., Brandt, E., Martin, D., Galbraith, A., Phornphutkul, C., Hunsakunachai, S., Manmontri, A., & Good, M. F. (1994). Towards a vaccine for rheumatic fever: Identification of a conserved target epitope on M protein of group A streptococci. Lancet, 344, 639–642.
Quinn, R. W. (1982). Epidemiology of group A streptococcal infections—their changing frequency and severity. Yale J Biol Med, 55, 265–270.
Raeder, R., Harokopakis, E., Hollingshead, S., & Boyle, M. D. (2000). Absence of SpeB production in virulent large capsular forms of group A streptococcal strain 64. Infect Immun, 68, 744–751.
Raeder, R., Woischnik, M., Podbielski, A., & Boyle, M. D. (1998). A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties. Res Microbiol, 149, 539–548.
Rakonjac, J. V., Robbins, J. C., & Fischetti, V. A. (1995). DNA sequence of the serum opacity factor of group A streptococci: Identification of a fibronectin-binding repeat domain. Infect Immun, 63, 622–631.
Rasmussen, M., & Bjorck, L. (2001). Unique regulation of SclB—a novel collagen-like surface protein of Streptococcus pyogenes. Mol Microbiol, 40, 1427–1438.
Rasmussen, M., Eden, A., & Bjorck, L. (2000). SclA, a novel collagen-like surface protein of Streptococcus pyogenes. Infect Immun, 68, 6370–6377.
Rasmussen, M., Muller, H. P., & Bjorck, L. (1999). Protein GRAB of Streptococcus pyogenes regulates proteolysis at the bacterial surface by binding alpha2-macroglobulin. J Biol Chem, 274, 15336–15344.
Riesenfeld-Orn, L, Wolpe, S., Garcia-Bustos, J. F, Hoffmann, M. K., & Tuomanen, E. (1989). Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components. Infect Immun, 57, 1890–1893.
Ruiz de Souza, V., Carreno, M. P., Kaveri, S. V., Ledur, A., Sadeghi, H., Cavaillon, J. M., Kazatchkine, M. D., & Haeffner-Cavaillon, N. (1995). Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol, 25, 1267–1273.
Ruoff, K. L. (1995). Streptococcus. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, & R. H. Yolken (Eds.), Manual of clinical microbiology, (pp. 299–307). Washington: ASM Press.
Salvadori, L. G., Blake, M. S., McCarty, M., Tai, J. Y., & Zabriskie, J. B. (1995). Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis, 171, 593–600.
Samuelsson, A., Towers, T. L., & Ravetch, J. V. (2001). Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science, 291, 484–486.
Schrager, H. M., Alberti, S., Cywes, C., Dougherty, G. J., & Wessels, M. R. (1998). Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. J Clin Invest, 101, 1708–1716.
Schuchat, A., Hilger, X, Zell, E., Farley, M. M., Reingold, A., Harrison, L., Lefkowitz, L., Danila, R., Stefonek, K., Barrett, N., Morse, D., & Pinner, R. (2001). Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis, 7, 92–99.
Schulze, K., Medina, E., Talay, S. R., Towers, R. J., Chhatwal, G. S., & Guzman, C. A. (2001). Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response. Infect Immun, 69, 622–625.
Schwartz, B., Facklam, R. R., & Breiman, R. F. (1990). Changing epidemiology of group A streptococcal infection in the USA. Lancet, 336, 1167–1171.
Shanley, T. P., Schrier, D., Kapur, V., Kehoe, M., Musser, J. M., & Ward, P. A. (1996). Streptococcal cysteine protease augments lung injury induced by products of group A streptococci. Infect Immun, 64, 870–877.
Sharief, M. K., Ingram, D. A., Swash, M., & Thompson, E. J. (1999). I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology, 52, 1833–1838.
Sharkawy, A., Low, D. E., Saginur, R., Gregson, D., Schwartz, B., Jessamine, P., Green, K., & McGeer, A. (2002). Severe group A Streptococcal soft-tissue infections in Ontario: 1992–1996. Clin Infect Dis, 34, 454–460.
Simpson, W. A., & Beachey, E. H. (1983). Adherence of group A streptococci to fibronectin on oral epithelial cells. Infect Immun, 39, 275–279.
Skansen-Saphir, U., Andersson, J., Bjorck, L., & Andersson, U. (1994). Lymphokine production induced by Streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol, 24, 916–922.
Spika, J. S., Peterson, P. K., Wilkinson, B. J., Hammerschmidt, D. E., Verbrugh, H. A., Verhoef, J., & Quie, P. G. (1982). Role of peptidoglycan from Staphylococcus aureus in leukopenia, thrombocytopenia, and complement activation associated with bacteremia. J Infect Dis, 146, 227–234.
Sriskandan, S., & Cohen, J. (1999). Gram-positive sepsis. Mechanisms and differences from Gramnegative sepsis. Infect Dis Clin North Am, 13, 397–412.
Sriskandan, S., McKee, A., Hall, L., & Cohen, J. (1997). Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother, 40, 275–277.
Stalhammar-Carlemalm, M., Areschoug, T., Larsson, C., & Lindahl, G. (1999). The R28 protein of Streptococcus pyogenes is related to several group B Streptococcal surface proteins, confers protective immunity and promotes binding to human epithelial cells. Mol Microbiol, 33, 208–219.
Standiford, T. J., Arenberg, D. A., Danforth, J. M., Kunkel, S. L., Van Otteren, G. M., & Strieter, R. M. (1994). Lipoteichoic acid induces secretion of interleukin-8 from humanblood monocytes: A cellular and molecular analysis. Infect Immun, 62, 119–125.
Stegmayr, B., Bjorck, S., Holm, S., Nisell, J., Rydvall, A., & Settergren, B. (1992). Septic shock induced by group A Streptococcal infection: Clinical and therapeutic aspects. Scand J Infect Dis, 24, 589–597.
Stevens, D. L. (1992). Invasive group A streptococcus infections. Clin Infect Dis, 14, 2–11.
Stevens, D. L. (1999). The flesh-eating bacterium: What’s next? J Infect Dis, 179(Suppl. 2), S366–S374.
Stevens, D. L., Gibbons, A. E., Bergstrom, R., & Winn, V. (1988). The Eagle effect revisited: Efficacy of clindamycin, erythromycin and penicillin in the treatment of streptococcal myositis. J Infect Dis, 158, 23–28.
Stevens, D. L., Tanner, M. H., Winship, J., Swarts, R., Ries, K. M., Schlievert, P. M., & Kaplan, E. (1989). Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Eng J Med, 321, 1–7.
Stevens, D. L., Yan, S., & Bryant, A. E. (1993). Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: An explanation for the inoculum effect. J Infect Dis, 167, 1401–1405.
Stockbauer, K. E., Magoun, L., Liu, M., Burns, E. H., Jr., Gubba, S., Renish, S., Pan, X., Bodary, S. C., Baker, E., Coburn, J., Leong, J. M., & Musser, J. M. (1999). A natural variant of the cysteine protease virulence factor of group A Streptococcus with an arginine-glycine-aspartic acid (RGD) motif preferentially binds human integrins alphavbeta3 and alphaIIbbeta3. Proc Natl Acad Sci USA, 96, 242–247.
Stromberg, A., Romanus, V., & Burman, L. G. (1991). Outbreaks of group A streptococcal bacteremia in Sweden: An epidemiologic and clinical study. J Infect Dis, 164, 595–598.
Stylianos, S., Wakabayashi, G., Gelfand, J. A., & Harris, B. H. (1991). Experimental hemorrhage and blunt trauma do not increase circulating tumor necrosis factor. J Trauma, 31, 1063–1067.
Svensson, M. D., Scaramuzzino, D. A., Sjobring, U., Olsen, A., Frank, C., & Bessen, D. E. (2000a). Role for a secreted cysteine proteinase in the establishment of host tissue tropism by group A streptococci. Mol Microbiol, 38, 242–253.
Svensson, N., Oberg, S., Henriques, B., Holm, S., Kallenius, G., Romanus, V., & Giesecke, J. (2000b). Invasive group A streptococcal infections in Sweden in 1994 and 1995: Epidemiology and clinical spectrum. Scand J Infect Dis, 32, 609–614.
Takei, S., Arora, Y. K., & Walker, S. M. (1993). Intravenous immunoglobulin contains antibodies inhibitory to activation of T-cells by staphylococcal superantigens. J Clin Invest, 91, 602–607.
The Working Group on Severe Streptococcal Infections. (1993). Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA, 269, 384, 390–391.
Timmerman, C. P., Mattsson, E., Martinez-Martinez, L., De Graaf, L., Van Strijp, J. A., Verbrugh, H. A., Verhoef, J., & Fleer, A. (1993). Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun, 61, 4167–4172.
Tuomanen, E., Liu, H., Hengstler, B., Zak, O., & Tomasz, A. (1985). The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis, 151, 859–868.
Ulrich, R. G., Olson, M. A., & Bavari, S. (1998). Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine, 16, 1857–1864.
Upton, M., Carter, P. E., Orange, G., & Pennington, T. H. (1996). Genetic heterogeneity of M type 3 group A streptococci causing severe infections in Tayside, Scotland. J Clin Microbiol, 34, 196–198.
Visvanathan, K., Charles, A., Bannan, J., Pugach, P., Kashfi, K., & Zabriskie, J. B. (2001). Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun, 69, 875–884.
Vugia, D. J., Peterson, C. L., Meyers, H. B., Kim, K. S., Arrieta, A., Schlievert, P. M., Kaplan, E. L., & Werner, S. B. (1996). Invasive group A streptococcal infections in children with varicella in Southern California. Pediatr Infect Dis J, 15, 146–150.
Wang, F. D., Liu, I. M., & Liu, C. Y. (2000a). In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium. Chung Hua I Hsueh Tsa Chih (Taipei.), 63, 119–123.
Wang, J. E., Jorgensen, P. F., Almlof, M., Thiemermann, C., Foster, S. J., Aasen, A. O., & Solberg, R. (2000b). Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect Immun, 68, 3965–3970.
Weisman, L. E., Cruess, D. E, & Fischer, G. W. (1994). Opsonic activity of commercially available standard intravenous immunoglobulin preparations. Pediatr Infect Dis J, 13, 1122–1125.
Welch, C. C., Tombridge, T. L., Baker, W. J., & Kinney, R. J. (1961). Beta-hemolytic streptococcal pneumonia. Report of an outbreak in a military population. Am J Med Sci, 242, 157–167.
Wessels, M. R., & Bronze, M. S. (1994). Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. Proc Natl Acad Sci USA, 91, 12238–12242.
Wexler, D. E., Chenoweth, D. E., & Cleary, P. P. (1985). Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci USA, 82, 8144–8148.
Wheeler, M. C., Roe, M. H., Kaplan, E. L., Schlievert, P. M., & Todd, J. K. (1991). Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates [see comments]. JAMA, 266, 533–537.
Wilson, G. J., Talkington, D. F., Gruber, W., Edwards, K., & Dermody, T. S. (1995). Group A streptococcal necrotizing fasciitis following varicella in children: Case reports and review. Clin Infect Dis, 20, 1333–1338.
Winram, S. B., & Lottenberg, R. (1996). The plasmin-binding protein Plr of group A streptococci is identified as glyceraldehyde-3-phosphate dehydrogenase. Microbiology, 142(Pt. 8), 2311–2320.
Yan, S., Bohach, G. A., & Stevens, D. L. (1994). Persistent acylation of high-molecular-weight penicillin-binding proteins by penicillin induces the postantibiotic effect in Streptococcus pyogenes. J Infect Dis, 170, 609–614.
Yan, S., Mendelman, P. M., & Stevens, D. L. (1993). The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4. FEMS Microbiol Lett, 110, 313–317.
Yang, K. D., Bathras, J. M., Shigeoka, A. O., James, J., Pincus, S. H., & Hill, H. R. (1989). Mechanisms of bacterial opsonization by immune globulin intravenous: Correlation of complement consumption with opsonic activity and protective efficacy. J Infect Dis, 159, 701–707.
Yong, J. M. (1994). Necrotising fasciitis. Lancet, 343, 1427.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Norrby-Teglund, A., McGeer, A., Kotb, M., Low, D.E. (2004). Severe Invasive Group a Streptococcal Infections. In: Fong, I.W., Drlica, K. (eds) Reemergence of Established Pathogens in the 21st Century. Emerging Infectious Diseases of the 21st Century, vol 2. Springer, Boston, MA. https://doi.org/10.1007/0-306-48411-0_1
Download citation
DOI: https://doi.org/10.1007/0-306-48411-0_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-47500-9
Online ISBN: 978-0-306-48411-7
eBook Packages: Springer Book Archive